Helius Medical Technologies to Release First Quarter of Fiscal Year 2020 Financial Results on May 7, 2020
April 22 2020 - 3:05PM
Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) (“Helius”
or the “Company”), a neurotech company focused on neurological
wellness, today announced that financial results for the quarter
ended March 31, 2020 will be released at 5:00 p.m. Eastern Time on
Thursday, May 7, 2020.
Management will host a conference call at 5:00 p.m. Eastern Time
on May 7, 2020 to discuss the financial results for the quarter
ended March 31, 2020. Those who would like to participate may dial
877-407-2988 (201-389-0923 for international callers) and provide
access code 13701495. A live webcast of the call will also be
provided on the Events section of the Company's investor relations
website and can be accessed directly via the following link:
https://78449.themediaframe.com/dataconf/productusers/hls/mediaframe/36950/indexl.html.
For those unable to participate, a replay of the call will be
available for two weeks at 877-660-6853 (201-612-7415 for
international callers); access code 13698861. The webcast will be
archived on the Events section of the Company’s investor relations
website.
About Helius Medical Technologies,
Inc.
Helius Medical Technologies is a neurotech
company focused on neurological wellness. The Company’s
purpose is to develop, license and acquire unique and non-invasive
platform technologies that amplify the brain’s ability to heal
itself. The Company’s first commercial product in Canada is
the Portable Neuromodulation Stimulator (PoNS™). For more
information, visit www.heliusmedical.com.
About the PoNS Device and PoNS
Treatment
The Portable Neuromodulation Stimulator (PoNS) is an authorized
class II, non-implantable medical device authorized for sale in
Canada. PoNS is intended as a short term treatment (14 weeks) of
chronic balance deficit due to mild-to-moderate traumatic brain
injury and is to be used in conjunction with physical therapy and
indicated as a short term treatment (14 weeks) of gait deficit due
to mild and moderate symptoms from MS and is to be used in
conjunction with physical therapy. The PoNS is an
investigational medical device in the United States, the European
Union, and Australia, and is currently under review for clearance
by the AUS Therapeutic Goods Administration. PoNS Treatment is
currently not commercially available in the United States, the
European Union or Australia.
Investor Relations Contact:
Westwicke Partners on behalf of Helius Medical Technologies,
Inc.
Mike Piccinino, CFA
investorrelations@heliusmedical.com
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From Apr 2024 to May 2024
Helius Medical Technolog... (NASDAQ:HSDT)
Historical Stock Chart
From May 2023 to May 2024